The Interaction between DNMT1 and High‐Mannose CD133 Maintains the Slow‐Cycling State and Tumorigenic Potential of Glioma Stem Cell

Yuanyan Wei,Qihang Chen,Sijing Huang,Yingchao Liu,Yinan Li,Yang Xing,Danfang Shi,Wenlong Xu,Weitao Liu,Zhi Ji,Bingrui Wu,Xiaoning Chen,Jianhai Jiang

DOI: https://doi.org/10.1002/advs.202202216

IF: 15.1

2022-07-19

Advanced Science

Abstract:The lower expression of MAN1A1 results in the formation of high‐mannose type N‐glycan of CD133 in GSCs. The interaction between high‐mannose CD133 and DNMT1 blocks the nuclear translocation of DNMT1. Activation of p21 and p27 expression by the CD133–DNMT1 interaction maintains glioma stem cell quiescence, self‐renewal, and tumorigenesis. The quiescent/slow‐cycling state preserves the self‐renewal capacity of cancer stem cells (CSCs) and leads to the therapy resistance of CSCs. The mechanisms maintaining CSCs quiescence remain largely unknown. Here, it is demonstrated that lower expression of MAN1A1 in glioma stem cell (GSC) resulted in the formation of high‐mannose type N‐glycan on CD133. Furthermore, the high‐mannose type N‐glycan of CD133 is necessary for its interaction with DNMT1. Activation of p21 and p27 by the CD133–DNMT1 interaction maintains the slow‐cycling state of GSC, and promotes chemotherapy resistance and tumorigenesis of GSCs. Elimination of the CD133–DNMT1 interaction by a cell‐penetrating peptide or MAN1A1 overexpression inhibits the tumorigenesis of GSCs and increases the sensitivity of GSCs to temozolomide. Analysis of glioma samples reveals that the levels of high‐mannose type N‐glycan are correlated with glioma recurrence. Collectively, the high mannose CD133–DNMT1 interaction maintains the slow‐cycling state and tumorigenic potential of GSC, providing a potential strategy to eliminate quiescent GSCs.

materials science, multidisciplinary,nanoscience & nanotechnology,chemistry